Can we fix ovarian aging? This startup is up to the task!
Female reproductive longevity and gender inequality are gaining more and more interest. It is one of the most exciting areas in the new longevity biotechnology field. Every venture firm is investing, incubating or searching for projects. BOLD Capital and Future Ventures are active partners in this field of science, as are Christian Angermayer and Bob Nelsen, two iconic biotechnology investors. Although women live longer than males, their reproductive years are limited. This is something that is often forgotten. The peak years of a female’s reproductive life are between late teens and early 20s. By the time women reach their mid-30s, fertility begins to decline. By the age of 45, women’s fertility has declined so drastically that it is difficult for them to get pregnant naturally. Women also begin their lives with a certain number of eggs, which is usually about one million. As women age, this number decreases. The ovaries age more quickly than the rest of a women’s body, a phenomenon that is understudied. We wouldn’t be here without them. It’s surprising how little we know about this avocado-shaped organ, which is found in half of humans.
They also affect a woman’s health and overall well-being. The ovaries also affect a woman’s overall health and well-being, as this organ loses its function faster with age than any other tissue. Asynchronous aging is the reason women’s fertility decreases and menopause occurs while still young.
In a previous article, I talked about Gameto. This biotechnology company is translating the effects of ovarian ageing to develop solutions that improve fertility and reduce the negative impact of menopause. Dina Radenkovic, Gameto’s CEO and co-founder, told me that she wanted to change the narrative about female reproductive longevity by focusing on health and longevity. Gameto has built a platform to improve assisted fertility and address menopause. Dina said she hopes that it will help women have fewer health issues in later life. The biomedical community has largely ignored the ovaries, except for their vital role in IVF treatment.